Brokers Offer Predictions for XENE FY2026 Earnings

Key Points

• Bloom Burton analysts predict Xenon Pharmaceuticals will report a fiscal year 2026 earnings per share (EPS) of ($4.89), which is lower than the consensus estimate of ($3.10) per share for the current year.
• Strong buy ratings from analysts contrast with a reported quarterly EPS of ($1.07), which was below the consensus estimate of ($1.03), indicating ongoing market challenges for the company.
• Institutional ownership in Xenon Pharmaceuticals is significant, with 95.45% of the stock held by institutional investors and hedge funds, reflecting strong investor interest despite recent performance.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Bloom Burton issued their FY2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Tuesday, October 7th. Bloom Burton analyst D. Martin forecasts that the biopharmaceutical company will post earnings of ($4.89) per share for the year. Bloom Burton currently has a "Strong-Buy" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Bloom Burton also issued estimates for Xenon Pharmaceuticals' FY2027 earnings at ($4.65) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period last year, the firm posted ($0.75) earnings per share.

XENE has been the subject of a number of other reports. Wells Fargo & Company initiated coverage on Xenon Pharmaceuticals in a research report on Wednesday, September 3rd. They set an "overweight" rating and a $48.00 price objective for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Xenon Pharmaceuticals in a research report on Saturday, September 27th. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Wedbush lifted their target price on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $53.30.

Xenon Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ:XENE opened at $39.16 on Wednesday. The business has a 50-day moving average price of $37.06 and a 200 day moving average price of $34.12. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -11.03 and a beta of 1.14. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the first quarter valued at approximately $30,000. Elevation Point Wealth Partners LLC acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $32,000. Osaic Holdings Inc. boosted its holdings in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. Finally, L1 Capital Pty Ltd acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $41,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 25,000 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $40.16, for a total value of $1,004,000.00. Following the completion of the transaction, the chief executive officer directly owned 31,302 shares of the company's stock, valued at $1,257,088.32. This represents a 44.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.07% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.